JLK, a Korean AI healthcare solutions company, announced Monday that it has signed a clinical research agreement with faculty members at Harvard Medical School, part of Massachusetts General Hospital (MGH) in the U.S.

Through collaboration with Harvard Medical School, JLK plans to validate and establish reliable clinical evidence for stroke solutions, the company said. 

In addition, the company said it will seek FDA approval for an AI-based stroke solution and pursue health insurance reimbursement in the U.S.

To establish a presence in the U.S. medical field, the company aims to expand its network through collaborations with reputable organizations like Harvard Medical School, while also fostering knowledge exchange to enhance technical capabilities.

JLK plans to apply for a U.S. patent for its stroke solution technology.

The company said it is making every effort to obtain health insurance reimbursement in the U.S. in 2024 and generate substantial sales in the medical field. However, the company did not provide details on the specific item it is seeking reimbursement for in the U.S.